Infection, Human Immunodeficiency Virus Clinical Trial
Official title:
A Single-Center Randomized, Open-Label, Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 LAP in Healthy Adult Subjects.
Verified date | April 2014 |
Source | ViiV Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a single-center, randomized, open-label, 3 parallel treatment study in healthy adult
subjects to assess the relative bioavailability of new formulations of GSK1265744 LAP 400 mg
intra muscular compared to the current GSK1265744 LAP 400 mg nanomilled formulation. This
study will evaluate LAP formulations of GSK1265744 with different particle sizes.
Following a 14 day lead in period with oral GSK1265744, forty-five subjects will receive 400
mg of one of three GSK1265744 formulations which vary in particle size from 200 nm to 5 um
by intramuscular injection. Samples for determination of GSK1265744 concentrations will be
collected for 12 weeks post-injection. Safety will be evaluated by adverse event recording
and laboratory values at frequent intervals throughout the trial. A subgroup of 12 subjects
will receive a 3 mg dose of oral midazolam at baseline on Day-29 and then again on the last
day of the oral GSK1265744 lead in period to evaluate the effect of GSK1265744 on CYP3A
enzymes.
The subjects will undergo follow-up evaluations for a minimum of 12 weeks.
Status | Completed |
Enrollment | 43 |
Est. completion date | April 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria - Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent. - Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. - A female subject is eligible to participate if she is of: non-childbearing potential. Female subjects of child bearing potential must agree to use contraception for at least 6 months after the final dose of study drug and should understand that drug concentrations may be measurable for up to one year after final dose. - Male subjects with female partners of child-bearing potential must agree to use one of the required contraception methods noted in the protocol. - Body weight >=50 Kilograms (kg) for men and >=45 kg for women and body mass index (BMI) within the range 18.5-31.0 kg/m^2 (inclusive). - Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <= 1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). - Single QTcB <450 msec. Exclusion Criteria: - A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening - Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). - A positive pre-study drug/alcohol screen. - A positive test for Human Immunodeficiency Virus (HIV) antibody. - History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 milliliters [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits. - History or regular use of tobacco-or nicotine-containing products within 3 months prior to screening. - The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). - Exposure to more than four new chemical entities within 12 months prior to the first dosing day. - Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. - History of sensitivity to any of the study medications, including midazolam and flumazenil, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. - History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. - Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. - Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing. - Lactating females. - Unwillingness or inability to follow the procedures outlined in the protocol. - Subject is mentally or legally incapacitated. - History of sensitivity to heparin or heparin-induced thrombocytopenia. - Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. - The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg. - History of clinically significant cardiovascular disease. - Any significant arrhythmia which, in the opinion of the principal Investigator and GSK Medical Monitor, will interfere with the safety for the individual subject. Non-sustained (>=3 consecutive ventricular ectopic beats) or sustained ventricular tachycardia. |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
ViiV Healthcare | GlaxoSmithKline |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma GSK1265744 area under the concentration-time curve for 12 weeks (AUC 0-wk12) | To evaluate the relative bioavailability of two new formulations of GSK1265744 400 mg LAP given intramuscularly compared to the current formulation (200 nm particle size) the pharmacokinetic (PK) parameters will include AUC 0 - 12 | Treatment Period: Day 1 pre-dose and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12 | No |
Primary | Plasma GSK1265744 last observed quantifiable concentration at week 12 (Cwk12) | To evaluate the relative bioavailability of two new formulations of GSK1265744 400 mg LAP given intramuscularly compared to the current formulation (200 nm particle size) the PK parameters will include Cwk12 | Week 12 | No |
Primary | Plasma GSK1265744 maximum observed concentration (Cmax) | To evaluate the relative bioavailability of two new formulations of GSK1265744 400 mg LAP given intramuscularly compared to the current formulation (200 nm particle size) the PK parameters will include the maximum observed concentration | Treatment period: Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12, Week 14 (follow-up) | No |
Secondary | Plasma GSK1265744 AUC(0-infinity) following the long acting parenteral (LAP) dosing | Plasma GSK1265744 AUC(0-infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing | Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (follow-up) | No |
Secondary | Plasma GSK1265744 AUC(0-wk4) and AUC(0-wk8) following the LAP dosing | Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing | Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8 | No |
Secondary | Plasma GSK1265744 Cwk4 and Cwk8 following the LAP dosing | Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing | Week 4 and Week 8 | No |
Secondary | Plasma GSK1265744 terminal phase half-life (t½) and time of occurrence of Cmax (tmax) following the LAP dosing | Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing | Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (Follow-up) | No |
Secondary | Plasma GSK1265744 apparent clearance (CL/F) following oral dosing | Plasma GSK1265744 AUC(0- infinity), AUC(0-wk4), Cwk4, AUC(0-wk8), Cwk8, t½, tmax, and CL/F following the LAP dosing | Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (Follow-up) | No |
Secondary | Plasma GSK1265744 AUC(0-wk12) and AUC(0-wk4) following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and 8 of LAI114433 (historical control) | Following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and Cohort 8 of LAI114433 (ClinicalTrials.gov Identifier: NCT01215006) for historical control Route C material.the following PK parameters will be determined AUC(0-wk12) and AUC(0-wk4) | Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week 12 | No |
Secondary | Plasma GSK1265744 Cwk12 following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and 8 of LAI114433 (historical control) | Following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and Cohort 8 of LAI114433 (ClinicalTrials.gov Identifier: NCT01215006) for historical control Route C material.the following PK parameter will be determined Cwk12 | Week 12 | No |
Secondary | Plasma GSK1265744 Cmax following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and 8 of LAI114433 (historical control) | Following LAP administration of 400 mg IM (unsplit) in Cohorts 3 and Cohort 8 of LAI114433 (ClinicalTrials.gov Identifier: NCT01215006) for historical control Route C material.the following PK parameter will be determined Cmax | Day 1 (pre-dose) and 4 hour (h) post dose, 48 h (Day 3), 96 h (Day 5), 144 h (Day 7), Week 2, Week 3, Week 4, Week 6, Week 8, Week12 and Week 14 (Follow-up) | No |
Secondary | Plasma GSK1265744 area under the concentration-time curve over the dosing interval (AUC(0-tau)) following oral administration of GSK1265744 with midazolam | Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined AUC(0-tau) | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma GSK1265744 Cmax following oral administration of GSK1265744 with midazolam | Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined -Cmax | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma GSK1265744 t½ and tmax following oral administration of GSK1265744 with midazolam | Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined t½ and tmax | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma GSK1265744 CL/F following oral administration of GSK1265744 with midazolam | Following the LAP administration of the GSK 1265744 with midazolam the following PK parameter will be determined CL/F | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma AUC(0-infinity) and last time of quantifiable concentration within a subject across all treatments (AUC(0-t)) of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744 | Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined: AUC(0-infinity) and (AUC(0-t)) | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex )of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744 | Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined: %AUCex | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma Cmax of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744 | Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined Cmax | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma t1/2, tlag and tmax of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744 | Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined t1/2, Lag time before observation of drug concentrations in sampled matrix (tlag)and tmax | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Plasma CL/F of midazolam following oral administration of midazolam alone and in combination with oral GSK1265744 | Following oral administration of midazolam alone and in combination with oral GSK1265744 the following PK parameters will be determined CL/F | During the oral lead in period: on Day -29, Day Day -28, Day -15, Day -14, Day -13 | No |
Secondary | Safety and tolerability assessed by the collection of all adverse events | Following administration of the study treatment safety and tolerability which includes adverse events (AEs) will be assessed. AEs will be collected from the start of study treatment and until the follow-up contact | Upto Week 14 | No |
Secondary | Safety and tolerability assessed by the collection of any use of concurrent medications | Following administration of the study treatment safety and tolerability which includes concurrent medications taken by the subjects will be assessed | Upto Week 14 | No |
Secondary | Safety and tolerability assessed by clinical laboratory screens | Following administration of the study treatment safety and tolerability which includes clinical laboratory screens will be assessed. Hematology, clinical chemistry, urinalysis | Day -1, Week 2, Week 4, Week 8, Week12 and Week 14 (Follow-up) | No |
Secondary | Safety and tolerability assessed by electrocardiograph (ECG) | Following administration of the study treatment safety and tolerability which includes ECG readings will be assessed. ECGs will be obtained at each timepoint during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcB intervals | Upto Week 14 | No |
Secondary | Safety and tolerability assessed by vital signs (blood pressure and pulse rate) | Following administration of the study treatment safety and tolerability which includes vital signs will be assessed. Vital sign measurements will include systolic and diastolic blood pressure and pulse rate | Upto Week 14 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01425099 -
Drug Interaction Study Between Dolutegravir and Prednisone
|
Phase 1 | |
Completed |
NCT01209117 -
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
|
Phase 1 | |
Completed |
NCT03231943 -
GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT01195974 -
A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
|
Phase 1 | |
Completed |
NCT02893488 -
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
|
Phase 1 | |
Terminated |
NCT01199731 -
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
|
Phase 2 | |
Completed |
NCT01449929 -
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
|
Phase 3 | |
Active, not recruiting |
NCT02951052 -
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
|
Phase 3 | |
Completed |
NCT01231516 -
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
|
Phase 3 | |
Completed |
NCT02273947 -
Food Effect Study With BMS-955176
|
Phase 1 | |
Completed |
NCT00071760 -
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
|
Phase 2 | |
Completed |
NCT02539576 -
Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
|
Phase 1 | |
Completed |
NCT01967771 -
Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT00774735 -
GSK1349572 Drug Interaction Study With Protease Inhibitors
|
Phase 1 | |
Completed |
NCT01077635 -
PENTA Fosamprenavir Study
|
N/A | |
Completed |
NCT00386347 -
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00945282 -
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
|
Phase 2 | |
Terminated |
NCT02576119 -
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
|
Phase 1 | |
Completed |
NCT02277600 -
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
|
Phase 1 | |
Completed |
NCT01077557 -
Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
|
N/A |